Gilead Profit Tops Expectations Despite Lower COVID Drug Sales, Outlook Raised
Gilead Sciences on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.
Reuters Health Information
source https://www.medscape.com/viewarticle/983145?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/983145?src=rss
Comments
Post a Comment